Two-year trial data back Abbott's Xience V DES over Boston's Taxus family
This article was originally published in Clinica
Executive Summary
Abbott's drug-eluting stent (DES) and the current US market leader, Xience V, has been shown safer and more effective than Boston Scientific's newer-generation Taxus Liberté DES at two years.